Company intelligence / Profile preview

BariaTek Medical

Paris, Île-de-France, Franceclinicaltrialsarena.com ↗

Ownership: Private
Development stage: Phase 1

Overview

BariaTek Medical has developed the BariTon™ device, a minimally invasive, reversible gastrointestinal implant designed to mimic the efficacy of bariatric surgery without permanent anatomical changes. The first-in-human implantation was completed in early 2024 with ongoing trials in Australia and Uzbekistan. No substantial clinical data have been published yet; initial results focus on feasibility and safety.

Therapeutic areas: Endocrinology
Modalities: Device (specifically, endoscopically delivered implant)
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

BariTon

Phase 1

Indications: Obesity, Type 2 diabetes mellitus

Partnerships

No major pharmaceutical or biotech partnerships disclosed as of June 2025. Investors include Bpifrance and Truffle Capital.

Beyond the preview

Go deeper on BariaTek Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BariaTek Medical.

Explore the full profile